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Abstract
Background: The novel water soluble compound STA-1474 is metabolized to ganetespib (formerly STA-9090), a potent
HSP90 inhibitor previously shown to kill canine tumor cell lines in vitro and inhibit tumor growth in the setting of murine
xenografts. The purpose of the following study was to extend these observations and investigate the safety and efficacy of
STA-1474 in dogs with spontaneous tumors.
Methods and Findings: This was a Phase 1 trial in which dogs with spontaneous tumors received STA-1474 under one of
three different dosing schemes. Pharmacokinetics, toxicities, biomarker changes, and tumor responses were assessed.
Twenty-five dogs with a variety of cancers were enrolled. Toxicities were primarily gastrointestinal in nature consisting of
diarrhea, vomiting, inappetence and lethargy. Upregulation of HSP70 protein expression was noted in both tumor
specimens and PBMCs within 7 hours following drug administration. Measurable objective responses were observed in
dogs with malignant mast cell disease (n=3), osteosarcoma (n=1), melanoma (n=1) and thyroid carcinoma (n=1), for a
response rate of 24% (6/25). Stable disease (.10 weeks) was seen in 3 dogs, for a resultant overall biological activity of 36%
(9/25).
Conclusions: This study provides evidence that STA-1474 exhibits biologic activity in a relevant large animal model of
cancer. Given the similarities of canine and human cancers with respect to tumor biology and HSP90 activation, it is likely
that STA-1474 and ganetespib will demonstrate comparable anti-cancer activity in human patients.
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Introduction
Heat shock protein 90 (HSP90), a molecular chaperone that
promotes the conformational maturation and stabilization of a
wide variety of client proteins, is a promising target for therapeutic
intervention in cancer[1,2,3,4]. Many HSP90 clients are known
oncoproteins, including EGFR family members, Akt, Bcr-Abl,
mutant p53, Kit, and Met, among others[1,3]. Inhibition of
HSP90 function promotes degradation of these client proteins
most often through the ubiquitin proteasome pathway ultimately
resulting in apoptosis[2,3,4]. Selectivity of HSP90 inhibitors for
malignant versus normal cells is believed to be conferred by the
fact that accumulation of over-expressed and mutated client
proteins promotes a shift to the active, super-chaperone complex
form of HSP90 in cancer cells[5,6,7]. In this state, a client protein
associates with HSP90 with the help of co-chaperones such as p23,
HSP40, HOP, and HIP[3,5,6]. This super-chaperone complex
exhibits enhanced ATPase activity, and consequently often binds
small molecule ATP mimetics with a higher affinity than the non-
complexed form of HSP90, leading to accumulation in tumors
relative to normal tissues. As such, the enhanced HSP90 activity
confers a greater sensitivity of malignant cells to the loss of HSP90
function[5]. Targeting HSP90 in cancer is also appealing as no
resistance mutations have been identified in this protein in human
cancers, suggesting it represents a relatively stable target for drug
treatment[8]. Because HSP90 inhibition can affect multiple
pathways that frequently contribute to the oncogenic process,
HSP90 inhibitors have the potential to demonstrate broad activity
across multiple tumor types[1,3].
The first class of HSP90 inhibitors was based on geldanamycin,
a benzoquinone ansamycin antibiotic that binds to the N-terminal
ATP-binding pocket of HSP90, thereby blocking its ATPase
function. Geldanamycin and its semi-synthetic derivatives 17-AAG
and 17-DMAG prevent the stabilization of client proteins,
ultimately resulting in their degradation[9,10,11]. However,
geldanamycin and its derivatives have a number of limitations
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hepatotoxicity[12]. STA-1474 (Synta Pharmaceuticals Corp,
Lexington, MA, USA) is a highly soluble prodrug of ganetespib
(formerly STA-9090), a novel resorcinol-containing compound
unrelated to geldanamycin that binds in the ATP-biding domain
at the N-terminus of HSP90 and acts as a potent HSP90 inhibitor.
Ganetespib induces degradation of multiple HSP90 client
proteins, killing a wide variety of human cancer cell lines at low
nanomolar concentrations in vitro, and exhibits potent anti-cancer
activity in xenograft tumor models in mice ([13,14,15]and
unpublished data, Synta Pharmaceuticals Corp.).
In previous studies, we demonstrated that ganetespib and its
water soluble prodrug STA-1474 have activity against canine
tumor cell lines[14,15]. Treatment of osteosarcoma (OSA) and
mast cell tumor (MCT) cell lines with either ganetespib or STA-
1474 induced growth inhibition, apoptosis that was caspase3/7
dependent, and inactivation and/or down-regulation of pKit/Kit,
pMet/Met, pAkt/Akt, and pSTAT3. Both ganetespib and STA-
1474 exhibited superior activity to the geldanamycin derivative
17-AAG. Ganetespib inhibited tumor growth in a murine MCT
xenograft model, while STA-1474 induced tumor regression,
caspase-3 activation and downregulation of phospho-Met (pMet)/
Met and p-Akt/Akt in OSA xenografts[14,15]. The purpose of the
following clinical trial was to extend our in vitro and murine studies
and investigate the safety and efficacy of STA-1474 in dogs with
spontaneous tumors as a prelude to future clinical work in humans
with cancer.
Materials and Methods
Eligibility
This clinical trial was approved by the Ohio State University
Veterinary Medical Center Hospital Executive Committee in July
2007. Written informed consent from the owner of each dog was
requested according to IACUC and The Ohio State University
College of Veterinary Medicine guidelines. STA-1474 was
administered to dogs with spontaneous tumors that had failed
conventional therapy or for which there were no therapeutic
alternatives, or for which conventional therapy was not desired by
the owner. To be eligible for the study, each dog must have been
diagnosed with one of a selected set of histologically confirmed
spontaneous malignancies, and have met all of the inclusion
criteria and none of the exclusion criteria. Eligible malignancies
included carcinomas, sarcomas, mast cell tumors, histiocytic
sarcomas, or lymphomas. Additional eligibility criteria included:
.1 year old at study entry; adequate organ function; at least 2
weeks since prior chemotherapy or radiation with complete
recovery from the acute toxicities of these treatments (3 weeks for a
surgical procedure); at least 1 week since prior treatment with any
other investigational drug; no diagnosis of leukemia; and no
evidence of brain metastases or any serious systemic disorder
incompatible with the study at the discretion of the investigator.
STA-1474 formulation
STA-1474, a soluble prodrug of ganetespib, was provided by
Synta Pharmaceuticals Corp (Figure 1). Lyophilized STA-1474
drug product was stored at 4uC and protected from light, until the
day of treatment. Drug was dissolved in Plasmalyte 148 USP and
pH was adjusted to the range of 6.0 to 7.0, using 0.1 N NaOH
standard solution for a final concentration of 3 mg/mL. The drug
solution was sterile filtered with 0.2 m nylon filter and loaded into a
non-DEHP fluid path IntraVia
TM 250 mL empty container. The
loaded infusion bag was then connected to a polyethylene lined
vented paclitaxel set, containing a 0.22 m filter, for administration.
Both the infusion bag and line were covered to protect from light.
Drug solution was used within 24 hours of preparation.
Study design
This study was a Phase I dose escalating, open label assessment
of the safety and pharmacokinetics of STA-1474 in client owned
dogs with spontaneous malignancies. Dogs were administered
STA-1474 on one of three dosing regimens and were evaluated
weekly or twice per week dependent on the regimen used.
Assessment of clinical toxicities and tumor response was performed
at each visit. Dogs were evaluated for hematologic and
biochemical toxicities every 7 days with routine bloodwork. The
initial dose of STA-1474 was set at 7 mg/kg based on previous
data from normal laboratory dogs (data not shown) and dose
escalation was set at 2.5 mg/kg increments in cohorts of 3 until
dose limiting toxicity (DLT) was identified. The DLT was
considered to be any grade 3 or 4 hematologic or non-hematologic
toxicity based on the established VCOG-CTAE criteria[16].
Additionally, any chronic non-grade 3 or 4 toxicities considered to
significantly impair quality of life (i.e., lethargy, inappetence) were
qualified as DLTs. Disease progression or signs and symptoms
definitely related to disease were not considered adverse events
(AEs).
Toxicity assessment
Each patient underwent a baseline complete history, physical
examination, and predose laboratory assessment that included a
complete blood count (CBC), serum biochemistry profile, and
urinalysis. Patients were assessed for adverse events on days 8, 15,
22, and 29, at which time a complete blood count with differential
and clinical chemistry were performed. Urinalysis was performed
at baseline and repeated only if indicated. Stipulations regarding
minimal hematological requirements to continue dosing were
included in the protocol: hematocrit .25%, neutrophils .1500/
L, platelets .100,000/L. In addition, liver transaminases were
required to be ,4X upper limit of normal with a normal total
bilirubin and serum creatinine to continue STA-1474 therapy.
Concomitant medications
To prevent or treat drug-related gastrointestinal toxicities,
supportive care was administered as needed to dogs enrolled in the
daily dosing cohorts. This typically consisted of famotidine,
metronidazole, loperamide, metoclopramide, ondansetron, and/
or maropitant. Antihistamines were administered to dogs with
mast cell tumors, as these tumors are known to release histamine.
Other supportive care administered to dogs consisted of
prednisone and non-steroidal anti-inflammatory medications to
treat tumor-associated inflammation, inappetence, and for pain
control.
Figure 1. Structure of STA-1474. Shown is the chemical structure of
STA-1474, a water-soluble phosphate prodrug of ganetespib.
doi:10.1371/journal.pone.0027018.g001
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Tumor assessments were completed prior to study entry, and
days 8, 15, 22, and 29. For dogs that continued beyond the
planned 4 doses of STA-1474, response assessments were
performed every 3–6 weeks thereafter, or at the time of suspected
tumor progression. Responses were assessed by the investigator
according to pre-defined protocol criteria. The response in dogs
with assessable disease was performed by clinical examination,
radiography, ultrasonography, or CT scans. Many lesions were
not amenable for quantitative radiographic imaging, but were
followed either by serial clinical examination (superficial lesions;
palpable lymph nodes) or by ultrasonography (abdominal lymph
nodes). Thoracic lesions were assessed by thoracic radiography
and nasal lesions by CT scan.
The response in dogs with measurable disease was judged by the
investigator on the basis of RECIST criteria[17]. A complete
response (CR) was defined as disappearance of all disease on two
measurements separated by a minimum period of 3 weeks. A
partial response (PR) was defined as greater than 30% reduction in
the sum of the longest diameter of the target lesions documented
by two assessments separated by at least 3 weeks. An increase of
.20% in the size of all measurable tumor areas as measured by
the sum of longest diameters of the target lesions taken as reference
the smallest sum since initiation of therapy, or the appearance of
any new lesion(s) would qualify as progressive disease (PD). A
mixed response (MR) was defined as PR in some target lesions
with PD in other target lesions. Stable disease (SD) was defined by
the absence of criteria for either a response or progression. Dogs
who had no evidence of tumor progression and who had not
experienced any unacceptable toxicity were eligible for extended
treatment cycles. Dose escalation in an individual dog was
permitted if the dog was tolerating therapy.
Ganetespib pharmacokinetics
Plasma samples were collected on day 1 and day 22 of therapy
at the specified intervals: before and after dosing at 30, 60, 90, 120,
180, 300 (5 hr), 540 (9 hr), and 1440 (24 hr) minutes relative to the
start of dosing. On day 8, day 15, and day 29, plasma was
collected before dosing only. Approximately 1 ml of blood was
drawn from an indwelling catheter, placed in a sodium heparin
vacuum glass tube, and placed on ice until centrifugation. Blood
samples were centrifuged at 3300 rpm for 10 minutes, within 30
minutes of collection. Plasma was transferred by pipette into two
cryovials and stored at 280uC until analysis.
Plasma concentrations of ganetespib were determined using a
qualified liquid chromatography tandem mass spectrometry (LC-
MS/MS) method. Samples were analyzed on an HPLC system
consisting of an Agilent HP1100 separation module (Santa Clara,
CA) coupled to an AB SCIEX API400 MS/MS detector (Foster
City, CA). Stable isotope-labeled ganetespib was used as an
internal standard. Sample extraction was performed by a liquid-
liquid extraction method with 25 mL plasma samples and 800 mL
methyl tertiary butyl ether. The organic phase of samples was
evaporated to dryness under nitrogen and reconstituted with
water/acetonitrile solution for injection. Chromatographic sepa-
ration was achieved on a reverse-phase analytical column (4 mm
particle, 5062.0 mm i.d.) with gradient elution of water/0.1%
formic acid and acetonitrile/0.1% formic acid at a flow rate of
500 mL/min. The total run time was 4 min. Quantitation was
achieved by MS/MS detection in positive ion mode by multiple
reaction monitoring. The lower limit of quantitation (LLOQ) was
1.00 ng/mL, with a concentration range from 1.00 to 1000 ng/
mL.
The pharmacokinetic parameters for ganetespib were deter-
mined from the plasma concentration data using the Noncompart-
mental Analysis module in WinNonlin, version 5.2 (Pharsight
Corporation, St.Louis, MO). The predose samples that measured
below the LLOQ (BQL) were treated as zero for the calculations.
Maximum concentration (Cmax) and time of maximum concen-
tration (Tmax) were directly determined from the observed
concentration-time profiles. The area under the plasma concen-
tration-time curve (AUC) was estimated by the linear trapezoidal
rule. The apparent half-life (t1/2) was calculated as t1/2=0.693/l
where l was the elimination rate constant estimated from the
regression of the terminal slope of the concentration versus time
curve.
Evaluation of HSP70 expression
Small biopsies were collected from a subset of patient tumors
that were accessible at 0, 7, and 24 hrs post treatment. Biopsies
were obtained using a 3 mm punch biopsy instrument or 14 gauge
Tru-cut needle. All samples were placed in cryovials, immediately
flash frozen in liquid nitrogen, and stored at 280uC until HSP70
analysis. To assess relative HSP70 levels in the collected tumor
samples, a commercially available HSP70-enzyme linked immu-
nosorbent assay (ELISA; Assay Designs, Ann Arbor, MI) was
performed. Frozen tumor samples were pulverized using a frozen
mortar and pestle. The resulting powder was resuspended in liquid
nitrogen, collected, then split between two 15 mL conicals; one
conical for ELISA and one for Western blot (see method below).
Once the liquid nitrogen evaporated away, the samples were
allowed to thaw on ice. Samples for ELISA were resuspended in
(1X) Extraction Reagent containing 1 mg/mL aprotinin, 1 mg/mL
leupeptin, 1 mg/mL pepstatin A, 1 mM PMSF, 1 mM sodium
orthovanadate, and10 mM sodium fluoride, using 1 mL for each
0.5 cm
3 of tissue. Samples were incubated on a rocker for 1 hour
at 4uC, centrifuged for 15 minutes at 4uC, and then supernatants
were collected. Bradford protein quantification assay was per-
formed on the extracts using BioRad Reagent (BioRad, Hercules,
CA). Samples were equalized to 250 ug/mL with (1X) Extraction
Reagent, aliquoted, and stored at 280uC until analysis. At a later
date, frozen samples where allowed to thaw on ice, then serially
diluted with Sample Diluent 2 (provided in kit) to 1:4, 1:16, and
1:32. 100 mL of each dilution was added to the appropriate wells,
in duplicate, of the 96-well pre-coated ELISA plate. The ELISA
was performed following the manufacturer’s instructions, and
absorbance was measured within 30 minutes using a Spectramax
microplate reader (Molecular Devices, Sunnyvale, CA) with
wavelength set at 450 nm and a correction wavelength at 540 nm.
To assess HSP70 levels in peripheral blood mononuclear cells,
8 mL of whole blood was collected before dosing and 24 hours
after treatment (in some cases also at 7 hours post treatment) on
day 1 and day 22 from the jugular vein into two 4 mL BD
Vacutainer CPT tubes (BD, Franklin Lakes, NJ). Samples were
kept at room temperature until centrifugation for 1 hour at 1600
RCF, within 2 hours of collection. After centrifugation, the
mononuclear cell layer in plasma was transferred to a 15 mL
conical. PBMCs were washed by adding 15 mL PBS and
centrifuging for 15 minutes at 300 RCF. After two washes, cell
pellets were resuspended in 1 mL PBS, and transferred to a
1.5 mL microcentrifuge tube. Cells were pelleted again by
centrifuging at 13,000 RCF for 1 minute. Supernatant was
removed and cell pellets where flash frozen in liquid nitrogen and
stored at 280uC. Immediately prior to analysis, PBMC pellets
were allowed to thaw on ice, then each sample was resuspended in
500 mL (1X) Extraction buffer with protease inhibitors. Using the
method described above, the samples were analyzed for relative
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immunosorbent assay (Assay Designs, Ann Arbor, MI).
Evaluation of tumor biopsies for HSP90 expression
Frozen tumor samples were processed as described above, then
resuspended in 100–150 uL of lysis buffer consisting of 20 mM
Tris-HCl pH 8.0, 137 mM NaCl, 10% glycerol, 1% IGEPAL CA-
630, 10 mM ethylenediaminetetraacetic acid (EDTA), 1 mg/mL
aprotinin, 1 mg/mL leupeptin, 1 mg/mL pepstatin A, 1 mM
phenylmethysulphonyl fluoride, 1 mM sodium orthovanadate,
10 mM sodium fluoride (all from Sigma, St. Louis, MO). Sample
were rocked at 4uC for 1 hour, and then centrifuged for 15
minutes at 13,000 RCF. A Bradford protein assay was performed
on the lysates using BioRad Reagent (Hercules, CA). 60–100 mgo f
protein were separated by SDS-page, and transferred to PVDF
membranes. The membranes were incubated overnight with anti-
HSP90 antibodies (Cell Signaling Technology, Danvers, MA),
washed, then incubated with horseradish peroxidase linked
secondary antibody. Membranes were washed again, then exposed
to Super Signal West Dura Extended Duration Substrate (Pierce,
Rockford, IL) Membranes were stripped, washed, and reprobed
for b-Actin (Santa Cruz Biotechnology, Santa Cruz, CA) using the
SNAP i.d. apparatus (Millipore, Billerica, MA) according to
manufacture’s instructions.
Results
Subjects
A total of 25 dogs with a variety of spontaneous cancers were
enrolled in the study. Patient demographics and tumor type are
listed in Table 1. The majority of dogs enrolled in this study had
failed prior treatment regimens (n=18, 72%) including surgery,
radiation therapy, chemotherapy, or a combination of these
treatments. Given the previous data demonstrating biologic
activity of ganetespib in canine osteosarcoma (OSA) and mast
cell tumor (MCT) cell lines, as well as evidence of tumor
regression/stabilization in murine xenograft models of canine
OSA and MCT, dogs with these tumor types were enriched in this
Phase I study. Tumor types represented included OSA (n=10),
MCT (n=4), thyroid carcinoma (n=3), lymphoma (n=3), other
carcinoma (n=2), nasal chondrosarcoma (n=1), oral malignant
melanoma (n=1), and oral fibrosarcoma (n=1).
Treatment groups and pharmacokinetic analysis
Dogs (n=12) were initially entered into a treatment regimen
consisting of STA-1474 administered intravenously over one hour
once per week. A second cohort of dogs (n=6) was administered
STA-1474 over 8 hours once per week. This dosing regimen was
chosen based on a partial response to therapy observed in one dog
with malignant melanoma in the first cohort following drug
extravasation and prolonged drug exposure due to slow subcuta-
neous absorption. The third cohort of dogs (n=7) received STA-
1474 administered over one hour twice per week. Each dog
entered into the study was intended to receive at least 4 doses of
STA-1474 with the option to continue treatment in the face of
either stable disease or an objective tumor response.
Pharmacokinetic data are summarized in Table 2. Full
pharmacokinetic sampling was performed for all dogs in this
study on the first day of drug administration. The mean plasma
concentration – time profiles for dogs in the three treatment
groups are shown in Figure 2a, with representative profiles for 6
dogs (2 in each treatment group) in Figure 2b. For dogs receiving
any of the three dosing regimens, the AUC was relatively similar,
ranging between 5013–5701 ng/ml-hr ganetespib. However, the
hourly drug infusions at 9.25 mg/kg or 5 mg/kg resulted in a
shorter Tmax (0.7 hr and 1.1 hr, respectively) and higher Cmax
(3982 ng/ml and 3415 ng/ml, respectively) compared to the
8 hour infusion (Tmax 5.7 hr, Cmax 802 ng/ml).
Safety evaluation
Adverse events during treatment cycles (summarized in Table 3)
consisted nearly entirely of gastrointestinal upset (anorexia,
nausea, vomiting, diarrhea) and lethargy. No drug-related
hematologic or biochemical toxicities were noted at any doses.
One dog with metastatic osteosarcoma developed acute anuric
renal failure resulting in euthanasia. Subsequent necropsy revealed
the presence of large tumor emboli in both renal arteries, with no
evidence of drug induced changes to the renal parenchyma, and as
such progressive disease was determined to be the cause of the
observed renal failure. A second dog developed acute liver
function test (ALT, ALP) and bilirubin elevations 24 hours
following drug administration. The dog subsequently vomited a
large foreign body consisting of gauze pads used for bandaging of
the catheter site and the biochemical values returned to normal
within 72 hours; a partial temporary obstruction of the common
bile duct due to foreign body was determined to be the cause of the
biochemical changes in this case.
Dose escalation was performed and dose limiting toxicities were
identified using the once per week hourly infusion. While nearly all
gastrointestinal toxicities were primarily grade 1 or 2 in nature, at
doses above 9.5 mg/kg, dogs were found to have lethargy and
anorexia that owners felt significantly impaired quality of life,
resulting in discontinuation of drug administration. For example,
all three dogs that received 10.25 mg/kg of drug experienced
grade 2 diarrhea, lethargy, and anorexia and each subsequently
received only one dose of drug. As such, 9.5 mg/kg was
considered to be the maximum tolerated weekly dose of drug
Table 1. Subject demographics.
Characteristics Total 1 hr 1x/wk 8 hr 1x/wk 1 hr 2x/wk
Number of dogs 25 12 6 7
Age
Median 9 9 7.5 9
Range 2–14 5–14 4–9 2–11
Gender
Male intact 1 1
Male neutered 9 2 3 4
Female neutered 15 9 3 3
Tumor Type
Osteosarcoma 10 5 3 2
Mast cell tumor 4 1 1 2
Thyroid carcinoma 3 1 2
Lymphoma 3 3
Other carcinoma 2 2
Nasal chondrosarcoma 1 1
Oral melanoma 1 1
Oral fibrosarcoma 1 1
Prior Treatment
Yes 18 8 6 4
No 7 4 3
doi:10.1371/journal.pone.0027018.t001
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gastrointestinal toxicities were manageable with the addition of
concomitant medications consisting of ondansetron, metoclopra-
mide and/or maropitant for nausea/vomiting and metronidazole
and/or loperamide for diarrhea. All dogs that continued on
therapy with STA-1474 beyond the initial 4 cycles of treatment
remained on concomitant medications for the duration of drug
treatment.
Response to therapy
Response rates were determined for dogs entered into the 3
different dosing groups. For dogs that received once per week
dosing regimen (n=12), no objective responses were noted with
the exception of one dog with an extensive oral malignant
melanoma that experienced an extravasation event during the 4
th
treatment with STA-1474. This dog had a partial response in
tumor size and following pharmacokinetic analysis (Figure 3), it
was determined that the inadvertent subcutaneous administration
resulted in an extended Tmax, without a significant change in the
actual AUC (data not shown).
Based on evidence of biologic activity associated with a longer
Tmax, pharmacokinetic modeling was employed to determine a
dosing model that would achieve a similar Tmax when drug was
delivered over a longer time period at the same dose rate. It was
predicted that 9.5 mg/kg of STA-1474 given over an 8 hour
infusion would result in plasma concentrations of ganetespib above
100 ng/ml of plasma for 8–10 hours and consequently the next 6
dogs were entered into a cohort evaluating this dosing regimen.
Additionally, two dogs from the first dosing cohort (9.5 mg/kg once
per week) were switched to the 8 hour infusion protocol after
finishing the planned 4 doses of drug. Of the 6 dogs initially treated
withthelongerinfusion,thereweretwopartial responses(metastatic
thyroid carcinoma, 36 weeks, Figure 4a; metastatic OSA, 20 weeks,
Figure 4b), one mixed response (metastatic MCT, 16 weeks), and
two dogs experienced stable disease (both with metastatic OSA, 12
weeks). One dog with metastatic thyroid carcinoma that switched
from the 1 hr to 8 hr infusion experienced stable disease for 40
weeks, and the dog with oral malignant melanoma and extravasa-
tion event experienced a continued partial response for 12 weeks
while on the 8 hour infusion protocol.
Since the longer infusion protocol appeared to be associated
with biologic activity, we wanted to determine whether more
frequent administration of STA-1474 using the 1 hour infusion
protocol would be both tolerable and induce objective responses to
therapy. A dose of 5 mg/kg administered over one hour twice per
week was chosen based on preliminary data of tolerability in
normal dogs and pharmacokinetic modeling (data not shown). As
shown in Figure 2a and b, this dosing regimen resulted in a Cmax
and AUC slightly lower than that generated by the 9.5 mg/kg
dose. Toxicities observed were similar to those with the once
weekly higher dose of STA-1474. Of the 7 dogs administered this
protocol, 2 experienced partial responses to therapy (both MCTs,
Figure 5) and both dogs went on to have their remaining disease
surgically excised. One dog (metastatic OSA) experienced stable
disease for a short period of time but the owner elected not to
continue therapy and as such, this did not meet RECIST criteria.
The remaining dogs (lymphoma, n=3; metastatic OSA, n=1)
experienced progressive disease.
Evaluation of HSP90 and HSP70 expression in tumor
samples and PBMCs
Following inhibition of HSP90, rapid upregulation of HSP70
expression is often noted[14,15,18]. As such, HSP70 upregulation
Figure 2. Pharmacokinetic analysis of STA-1474 following
administration using three different dosing regimens. a) Mean
ganetespib plasma concentration – time profile for each dosing
regimen b) Representative ganetespib plasma concentration – time
profiles for two patients in each dosing regimen.
doi:10.1371/journal.pone.0027018.g002
Table 2. Mean pharmacokinetic parameters of STA-9090.
STA-1474 Dose Infusion Treatment t1/2 Tmax Cmax AUClast
(mg/kg) (h) Frequency (h) (h) (ng/mL) (ng/mL?h)
9.5 1 Once weekly 5.6 0.7 3982 5701
9.5 8 Once weekly NR* 5.7 802 5605
5 1 Twice weekly 6.1 1.1 3415 5013
*NR: not reportable due to insufficient terminal phase characterization.
doi:10.1371/journal.pone.0027018.t002
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determine whether treatment with STA-1474 altered the expres-
sion of HSP70, and if HSP70 could serve as a potential sensitive
surrogate biomarker for HSP90 inhibition PBMCs were collected
pre and post treatment and Western blotting for HSP70 was
performed. As shown in Figure 6a, small increases in HSP70
expression were apparent in the post treatment PBMC samples,
although these changes were difficult to accurately quantitate.
Consequently, an ELISA assay was used on subsequent samples to
more definitively assess upregulation of HSP70. Figure 6b
demonstrates that upregulation of HSP70 in the tumors and
PBMCs was more accurately assessed using the ELISA assay.
Moreover, these data indicate that changes in HSP70 expression
within PBMCs following STA-1474 treatment can be used as a
surrogate marker of HSP70 upregulation within tumors. Lastly,
HSP90 was expresed in all tumor samples and expression levels
did not appear to change substantially 24 hrs following treatment
with STA-1474 (Figure 6c).
Discussion
HSP90, a molecular chaperone with several client proteins
known to contribute to tumorigenesis, has arisen as a promising
target for therapeutic intervention in a variety of cancers. Biologic
activity of the benzoquinone ansamycin antibiotic geldanamycin
and its semi-synthetic derivatives 17-AAG and 17-DMAG has
been demonstrated in vivo and in murine xenograft models for
various hematopoietic neoplasms and solid carcino-
mas[19,20,21,22]. Additionally, several clinical trials evaluating
geldanamycin derivatives and other novel HSP90 inhibitors have
been completed and several are ongoing. However, despite
encouraging results in vitro and in mouse models, biologic activity
of many of the HSP90 inhibitors has not been as significant as
predicted based on experimental models. The reasons for this are
multi-factorial and include the fact that inhibition of HSP90 results
in upregulation of other chaperones or co-chaperones (HSP70/
HSP27) capable of influencing protein stabilization[23]; co-
chaperones CDC37, AHA1 and p23 are highly expressed in
cancer cells and may enhance the function of HSP90 in the
presence of inhibitors[24,25,26]; mitochondrial HSP90 is usually
not affected by the HSP90 inhibitors now in clinical trials[27,28];
current dosing/administration schedules may not provide suffi-
cient inhibition of tumor HSP90 activity[1]; and tumor cell
reliance on driver proteins (HER2, Kit, etc) that are HSP90 clients
may be required for substantial anti-tumor activity. Given that
significant barriers to the effective use of HSP90 inhibitors in the
clinical setting still exist, a spontaneous tumor model that more
closely recapitulates human cancers would be useful to begin to
explore treatment strategies more likely to result in clinical benefit.
As such, the purpose of this clinical study was to evaluate the safety
and activity of STA-1474, a water soluble prodrug of the
resorcinol-containing compound ganetespib, in pet dogs with
spontaneous cancers.
Ganetespib possesses a number of advantages over geldanamy-
cin and its semi-synthetic derivatives 17-AAG and 17-DMAG
including lack of hepatotoxicity and activity at lower drug
concentrations. In our previous work with ganetespib and its
prodrug STA-1474, we demonstrated that HSP90 inhibition
resulted in downregulation of client proteins Kit, Met, and Akt in
canine MCT and OSA cell lines, resulting in apoptosis[14,15].
Biologic effects of ganetespib were demonstrated at concentrations
at least 1 log lower than those for 17-AAG. Furthermore, we were
able to demonstrate anti-tumor activity of ganetespib against
canine MCT and OSA xenografts including downregulation of
Met and Akt in vivo. STA-1474 was chosen for further study in pet
dogs with cancer due to its solubility in water which facilitated
administration in the clinical setting.
The demographics of subjects in the study population were
similar to those for dogs enrolled in previously reported Phase I
Table 3. Enrollment and toxicity by dose/regimen.
Regimen Dose (mg/kg) No. of dogs Lethargy Anorexia Vomiting Diarrhea
123123123123
1 hr/week 7.0 4 2 2 3 2 3
9.5 5 1 1 2 1 1
1 0 . 2 5 3 3313
8 hr/week 9.5 6 2 5 4 3 4 4
1 hr/2x week 5.0 7 4 2 3 5 5 1 1
doi:10.1371/journal.pone.0027018.t003
Figure 3. Serial CT demonstrating regression of oral malignant
melanoma following treatment with STA-1474. Patient # 5 had
an aggressive oral malignant melanoma that had invaded into the nasal
cavity. During the 4
th treatment cycle with STA-1474, an extravasation
event occurred resulting in altered drug pharmacokinetics. A marked
decrease in the oral mass was observed 7 days later and a subsequent
CT scan confirmed a partial response to therapy. Shown are two
representative matched CT images of tumor before and after treatment.
doi:10.1371/journal.pone.0027018.g003
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placed on enrolling dogs with either OSA or MCT given the prior
studies in vitro and mouse models suggesting HSP90 inhibition
would likely have biologic activity in these tumor types. Nearly all
adverse events observed in this study were gastrointestinal in
nature (anorexia, lethargy, vomiting, and diarrhea) and most were
readily manageable with concomitant medications. Importantly,
there was no evidence of hematologic toxicity at any of the doses
or regimens used indicating that it may be possible to combine
ganetespib with other anti-tumor agents that typically exhibit
myelosuppression (i.e., chemotherapeutics) without enhanced
toxicity. Seven of the 25 dogs (28%) received more than 8 doses
of STA-1474 (range 10–38) with the longest dog on study receiving
38 treatments. No hematologic or biochemical consequences of
long-term administration of STA-1474 were observed in these
dogs, again indicating that prolonged HSP90 inhibition with
ganetespib did not affect the bone marrow stem cell compartment
or result in liver or renal toxicity.
While objective responses to therapy were observed in this
study, nearly all occurred using a dosing regimen that was not
originally planned. A dog with oral melanoma in the first dosing
cohort received most of the drug subcutaneously as the
intravenous catheter was dislodged during the course of admin-
istration. Pharmacokinetic analysis revealed an extremely long
Tmax associated with sustained blood levels of STA-9090 between
200–600 ng/ml for 8–10 hours. As this was the only patient
within the first dosing cohort that exhibited a biologic response to
therapy, an additional treatment group was added using an
infusion protocol designed to replicate the extravasation event.
The objective response rate in this second group was 30% (2PR/6)
Figure 4. Response of metastatic thyroid carcinoma and OSA to STA-1474 treatment. a) Patient #14 had a locally recurrent thyroid
carcinoma with metastatic disease to the lungs. This patient received STA-1474 on the 8 hour infusion protocol and experienced a partial response to
therapy of both the locally recurrent and metastatic disease. Shown are representative radiographs before and after 15 treatments with STA-1474.
The yellow arrows point to the metastatic pulmonary nodules. b) Patient #18 had metastatic OSA to the lungs following amputation and
chemotherapy for an appendicular OSA. This patient received STA-1474 on the 8 hour infusion protocol and experienced a partial response to
therapy. Shown are representative radiographs before and after 4 treatments with STA-1474. The yellow arrows point to the metastatic pulmonary
nodules.
doi:10.1371/journal.pone.0027018.g004
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Importantly, 3 dogs with metastatic OSA derived clinical benefit
from STA-1474 treatment in the 8 hour dosing group as opposed
to the 7 dogs with OSA that did not derive benefit when treated
with the 1 hour dosing regimens. It is therefore possible that
longer infusion of STA-1474 induced more sustained inhibition of
HSP90 function resulting in enhanced biologic activity.
We documented rapid upregulation of HSP70 expression in
both tumor samples and PBMCs that occurred within 7 hours
following STA-1474 treatment. It is known that HSF-1-dependent
HSP70 and HSP27 upregulation frequently occurs following loss
of HSP90 function[23,30,31]. HSP70 inhibits multiple aspects of
the apoptotic cascade, including release of cytochrome C and
apoptosis-inducing factor (AIF), nuclear import of AIF, and
activation of procaspases 9 and 3 and as such, its upregulation may
also act to protect tumor cells from apoptosis[32]. Recent evidence
indicates that upregulation of HSP70 and HSP27 may promote
resistance to HSP90 inhibitors as silencing of HSP70 and/or
HSP27 significantly increases tumor cell sensitivity to geldanamy-
cin[30,31]. The effects of combined HSP90/HSP70 inhibition
have not yet been investigated in the clinical setting, but such an
approach may provide more durable anti-tumor activity. Indeed,
although partial responses to therapy were observed in our study,
no complete responses occurred and all dogs that experienced a
PR or SD eventually developed progressive disease.
The biologic activity of STA-1474 we observed in dogs with
metastatic OSA is important as this disease serves as a relevant
model of OSA in humans[33,34]. In both dogs and humans, no
significant improvements in survival have occurred over the past
10–15 years and chemotherapy resistant metastases are common
Figure 5. Response of cutaneous mast cell tumors to STA-1474 treatment. a) Patient #19 had recurrent grade 3 cutaneous MCTs. This
patient received STA-1474 on the 1 hour infusion protocol twice per week and experienced a partial response to therapy of the cutaneous lesions
after 7 treatments. b) Patient #24 had a large previously untreated cutaneous MCT. This patient received STA-1474 on the 1 hour infusion protocol
twice per week and experienced a partial response to therapy of the cutaneous lesions after 4 treatments.
doi:10.1371/journal.pone.0027018.g005
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treated with surgical resection and adjuvant chemotherapy
remains at 60–70% while the 2 year survival rate for dogs with
appendicular OSA treated with amputation and standard
chemotherapy is only 10–20%[33,35,36]. It is possible that the
addition of chemotherapy to STA-1474 treatment may promote
enhanced cell killing of OSA cells, as loss of HSP90 function may
induce rapid modulation of key cell signaling proteins vital for
apoptosis protection thereby sensitizing these cells to DNA
damaging agents. We are currently investigating the effects of
combined or sequential treatment of OSA cell lines with
chemotherapy (doxorubicin, platinum agents) and ganetespib to
determine if synergistic interactions can be identified. Additionally,
recent data suggest that loss of proteasome function may enhance
the effects of HSP90 inhibition[37]; potential synergistic interac-
tions of bortezimib and STA-1474 are therefore being explored.
Lastly, we did observe an objective response to STA-1474 in a dog
with oral melanoma. Activity of HSP90 inhibitors has been
observed against metastatic melanoma in human patients, and
there is now evidence suggesting a role for phospholipase A2
activation in the Hsp90 inhibitor-induced metabolic response[38].
This deserves further evaluation in melanoma as well as other solid
tumors as it may represent another mechanism through which
synergistic anti-tumor activity can be achieved.
In summary, we describe a preclinical proof-of-concept Phase I
study of STA-1474, a water-soluble prodrug of the potent HSP90
inhibitor ganetespib in a relevant large animal model of
spontaneous naturally occurring cancer. This study provided
Figure 6. Analysis of HSP90 and HSP70 expression in dogs before and after treatment with STA-1474. a) PBMCs were collected from
normal control dogs (cont 1 and cont 2) and study dogs before and 24 hours after treatment with STA-1474 at 9.5 mg/kg over 8 hours. Protein
lysates were generated and following SDS-PAGE, Western blotting was performed for HSP70. Blots were then stripped and reprobed for b-actin. b)
Tumor biopsies and PBMCs were collected from dogs treated with 5 mg/kg STA-1474 over 1 hour before treatment and at 7 and 24 hours post
treatment. Protein lysates were generated and an ELISA was performed to detect HSP70. Results are expressed as HSP70 protein (ng/ml) and percent
of baseline. c) Protein lysates generated from the tumor biopsies described above were subjected to SDS-PAGE followed by Western blotting for
HSP90. Blots were then stripped and re-probed for b-actin.
doi:10.1371/journal.pone.0027018.g006
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events likely to occur in human clinical trials with ganetespib,
evidence that hematologic and biochemical toxicities are unlikely
to arise during therapy, demonstration of biologic activity in a
pretreated patient population, and importantly, tolerability of drug
administration over multiple cycles of therapy. These data laid the
groundwork for the current clinical studies of ganetespib in
humans with cancer.
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